Literature DB >> 21726674

Proteomic identification of specifically carbonylated brain proteins in APP(NLh)/APP(NLh) × PS-1(P264L)/PS-1(P264L) human double mutant knock-in mice model of Alzheimer disease as a function of age.

Rukhsana Sultana1, Renã A S Robinson, Fabio Di Domenico, Hafiz Mohmmad Abdul, Daret K St Clair, William R Markesbery, Jian Cai, William M Pierce, D Allan Butterfield.   

Abstract

Alzheimer disease (AD) is the most common type of <span class="Disease">dementia and is characterized pathologically by the presence of neurofibrillary tangles (NFTs), senile plaques (SPs), and loss of synapses. The main component of SP is amyloid-beta peptide (Aβ), a 39 to 43 amino acid peptide, generated by the proteolytic cleavage of amyloid precursor protein (APP) by the action of beta- and gamma-secretases. The presenilins (PS) are components of the γ-secretase, which contains the protease active center. Mutations in PS enhance the production of the Aβ42 peptide. To date, more than 160 mutations in PS1 have been identified. Many PS mutations increase the production of the β-secretase-mediated C-terminal (CT) 99 amino acid-long fragment (CT99), which is subsequently cleaved by γ-secretase to yield Aβ peptides. Aβ has been proposed to induce oxidative stress and neurotoxicity. Previous studies from our laboratory and others showed an age-dependent increase in oxidative stress markers, loss of lipid asymmetry, and Aβ production and amyloid deposition in the brain of APP/PS1 mice. In the present study, we used APP (NLh)/APP(NLh) × PS-1(P246L)/PS-1(P246L) human double mutant knock-in APP/PS-1 mice to identify specific targets of brain protein carbonylation in an age-dependent manner. We found a number of proteins that are oxidatively modified in APP/PS1 mice compared to age-matched controls. The relevance of the identified proteins to the progression and pathogenesis of AD is discussed.
Copyright © 2011 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21726674      PMCID: PMC3199338          DOI: 10.1016/j.jprot.2011.06.015

Source DB:  PubMed          Journal:  J Proteomics        ISSN: 1874-3919            Impact factor:   4.044


  98 in total

Review 1.  Evidence of oxidative damage in Alzheimer's disease brain: central role for amyloid beta-peptide.

Authors:  D A Butterfield; J Drake; C Pocernich; A Castegna
Journal:  Trends Mol Med       Date:  2001-12       Impact factor: 11.951

Review 2.  The 14-3-3 proteins: gene, gene expression, and function.

Authors:  Yasuo Takahashi
Journal:  Neurochem Res       Date:  2003-08       Impact factor: 3.996

Review 3.  Protein oxidation in aging, disease, and oxidative stress.

Authors:  B S Berlett; E R Stadtman
Journal:  J Biol Chem       Date:  1997-08-15       Impact factor: 5.157

4.  The prolyl isomerase Pin1 restores the function of Alzheimer-associated phosphorylated tau protein.

Authors:  P J Lu; G Wulf; X Z Zhou; P Davies; K P Lu
Journal:  Nature       Date:  1999-06-24       Impact factor: 49.962

Review 5.  Lipid peroxidation and protein oxidation in Alzheimer's disease brain: potential causes and consequences involving amyloid beta-peptide-associated free radical oxidative stress.

Authors:  D Allan Butterfield; Christopher M Lauderback
Journal:  Free Radic Biol Med       Date:  2002-06-01       Impact factor: 7.376

6.  Respiratory chain enzyme activities in isolated mitochondria of lymphocytes from patients with Alzheimer's disease.

Authors:  J A Molina; F de Bustos; F J Jiménez-Jiménez; J Benito-León; T Gasalla; M Ortí-Pareja; L Vela; F Bermejo; M A Martín; Y Campos; J Arenas
Journal:  Neurology       Date:  1997-03       Impact factor: 9.910

7.  Protein carbonyl groups as biomarkers of oxidative stress.

Authors:  Isabella Dalle-Donne; Ranieri Rossi; Daniela Giustarini; Aldo Milzani; Roberto Colombo
Journal:  Clin Chim Acta       Date:  2003-03       Impact factor: 3.786

8.  Proteomic identification of oxidatively modified proteins in Alzheimer's disease brain. Part I: creatine kinase BB, glutamine synthase, and ubiquitin carboxy-terminal hydrolase L-1.

Authors:  Alessandra Castegna; Michael Aksenov; Marina Aksenova; Visith Thongboonkerd; Jon B Klein; William M Pierce; Rosemarie Booze; William R Markesbery; D Allan Butterfield
Journal:  Free Radic Biol Med       Date:  2002-08-15       Impact factor: 7.376

9.  Proteomics-determined differences in the concanavalin-A-fractionated proteome of hippocampus and inferior parietal lobule in subjects with Alzheimer's disease and mild cognitive impairment: implications for progression of AD.

Authors:  Joshua B Owen; Fabio Di Domenico; Rukhsana Sultana; Marzia Perluigi; Chiara Cini; William M Pierce; D Allan Butterfield
Journal:  J Proteome Res       Date:  2009-02       Impact factor: 4.466

10.  Redox proteomic identification of 4-hydroxy-2-nonenal-modified brain proteins in amnestic mild cognitive impairment: insight into the role of lipid peroxidation in the progression and pathogenesis of Alzheimer's disease.

Authors:  Tanea Reed; Marzia Perluigi; Rukhsana Sultana; William M Pierce; Jon B Klein; Delano M Turner; Raffaella Coccia; William R Markesbery; D Allan Butterfield
Journal:  Neurobiol Dis       Date:  2008-01-05       Impact factor: 5.996

View more
  12 in total

Review 1.  Abeta, oxidative stress in Alzheimer disease: evidence based on proteomics studies.

Authors:  Aaron M Swomley; Sarah Förster; Jierel T Keeney; Judy Triplett; Zhaoshu Zhang; Rukhsana Sultana; D Allan Butterfield
Journal:  Biochim Biophys Acta       Date:  2013-10-09

Review 2.  Redox proteomics and amyloid β-peptide: insights into Alzheimer disease.

Authors:  D Allan Butterfield; Debra Boyd-Kimball
Journal:  J Neurochem       Date:  2018-11-27       Impact factor: 5.372

Review 3.  Neurodegeneration and Alzheimer's disease (AD). What Can Proteomics Tell Us About the Alzheimer's Brain?

Authors:  Guillermo Moya-Alvarado; Noga Gershoni-Emek; Eran Perlson; Francisca C Bronfman
Journal:  Mol Cell Proteomics       Date:  2015-12-11       Impact factor: 5.911

Review 4.  The 2013 SFRBM discovery award: selected discoveries from the butterfield laboratory of oxidative stress and its sequela in brain in cognitive disorders exemplified by Alzheimer disease and chemotherapy induced cognitive impairment.

Authors:  D Allan Butterfield
Journal:  Free Radic Biol Med       Date:  2014-07-01       Impact factor: 7.376

5.  Global analysis of S-nitrosylation sites in the wild type (APP) transgenic mouse brain-clues for synaptic pathology.

Authors:  Monika Zaręba-Kozioł; Agnieszka Szwajda; Michał Dadlez; Aleksandra Wysłouch-Cieszyńska; Maciej Lalowski
Journal:  Mol Cell Proteomics       Date:  2014-06-03       Impact factor: 5.911

Review 6.  Dynamic Interplay between Copper Toxicity and Mitochondrial Dysfunction in Alzheimer's Disease.

Authors:  Giusy Tassone; Arian Kola; Daniela Valensin; Cecilia Pozzi
Journal:  Life (Basel)       Date:  2021-04-24

7.  Discovering context-specific relationships from biological literature by using multi-level context terms.

Authors:  Sejoon Lee; Jaejoon Choi; Kyunghyun Park; Min Song; Doheon Lee
Journal:  BMC Med Inform Decis Mak       Date:  2012-04-30       Impact factor: 2.796

8.  Brain site-specific proteome changes in aging-related dementia.

Authors:  Arulmani Manavalan; Manisha Mishra; Lin Feng; Siu Kwan Sze; Hiroyasu Akatsu; Klaus Heese
Journal:  Exp Mol Med       Date:  2013-09-06       Impact factor: 8.718

9.  Degenerative alterations in noradrenergic neurons of the locus coeruleus in Alzheimer's disease.

Authors:  Lihua Liu; Saiping Luo; Leping Zeng; Weihong Wang; Liming Yuan; Xiaohong Jian
Journal:  Neural Regen Res       Date:  2013-08-25       Impact factor: 5.135

Review 10.  Lipid rafts participate in aberrant degradative autophagic-lysosomal pathway of amyloid-beta peptide in Alzheimer's disease.

Authors:  Xin Zhou; Chun Yang; Yufeng Liu; Peng Li; Huiying Yang; Jingxing Dai; Rongmei Qu; Lin Yuan
Journal:  Neural Regen Res       Date:  2014-01-01       Impact factor: 5.135

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.